Glutathione S-transferase p1 and DNA polymorphisms with the response to chemotherapy and the prognosis of bone Tumor

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5883-5886

  Yang, Li Min ^a   Li, Xiu Hua ^a   Bao, Cui Fen ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; DNA repaird gene; GSTP1; Polymorphisms; Response

Indexed keywords

EID: 84874024558     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5883     Document Type: Article

References (17)

1. Caronia D, Patiño-García A, Milne RL, et al (2009). Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J, 9, 347-53.
2. Fuchs B, Zhang K, Schabel A, et al (2001). Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene, 278, 245-52.
3. Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev, 11, 1513-30.
4. Hao T, Feng W, Zhang J, Sun YJ, Wang G (2012). Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients. Asian Pac J Cancer Prev, 13, 3821-4.
5. Hengstler JG, Arand M, Herrero ME, et al (1998). Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase, and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res, 154, 47-85.
6. Ketterer B (1988). The protective role of glutathione transferases in mutagenesis and carcinogenesis. Mutat Res, 202, 343-61.
7. Kweekel DM, Gelderblom H, Antonini NF, et al (2009). Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer, 45, 572-8.
8. Mirabello L, Troisi RJ, Savage SA (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer, 125, 229-234.
9. Pasello M, Manara MC, Michelacci F, et al (2011). Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal Cell Pathol (Amst), 34, 131-45.
10. Pasello M, Michelacci F, Scionti I, et al (2008). Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res, 68, 6661-8.
11. Riddick DS, Lee C, Ramji S, et al (2005). Cancer chemotherapy and drug metabolism. Drug Metab Dispos, 33, 1083-96.
12. Stoehlmacher J, Park DJ, Zhang W, et al (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94, 936-42.
13. U.S. Cancer Statistics Working Group (2009). United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. Available at: http://www.cdc. gov/cancer/ npcr/npcrpdfs/US_Cancer_Statistics_2004_Incidence_and_ Mortality.pdf. Oct. 2011.
14. Windsor RE, Strauss SJ, Kallis C, et al (2012). Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer, 118, 1856-67.
15. Wang X, Zuckerman B, Pearson C, et al (2002). Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA, 287, 195-202.
16. Zhang SL, Mao NF, Sun JY, Shi ZC, Wang B, Sun YJ (2012). Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy. Asian Pac J Cancer Prev, 13, 2705-9.
17. Zimniak P, Nanduri B, Pikula S, et al (1994). Naturally occurring human glutathione S-transferase GSTP-1 isoforms with isoleucin and valine in position 104 differ in enzymic properties. Eur J Biochem, 224, 893-9